This week on "The Top Line," we're diving into the details of the spree of big-money biopharma deals in 2023 and examining what that means for this year.

Fierce Pharma Senior Writer Kevin Dunleavy sits down with Cody Powers, a consultant who advises companies on business development and franchise growth strategy, to discuss the reasons behind the numerous high-value deals in 2023, which companies are primed to make major moves this year, and whether the trend of acquiring ADCs and obesity treatments will continue. 

To learn more about the topics in this episode: 

• The top 10 biopharma M&A deals of 2023
• 2024 forecast: M&A saw an uptick in 2023. Analysts expect the trend to continue
• For biopharma M&A, the best returns come from small deals: analysts

See omnystudio.com/listener for privacy information.